Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 3/20 | 0.30 |
| ▸ | BTK | Q06187 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23009188 | 0.90 | LPL (0.35) | LPLLIPGCYP2A6 | |
| SCHEMBL15392068 | 0.78 | LPL (0.39) | LPLLIPG | |
| SCHEMBL26621977 | 0.78 | LPL (0.35) | LPLLIPG | |
| SCHEMBL24985353 | 0.78 | LPL (0.36) | LPLLIPG | |
| SCHEMBL30640483 | 0.78 | LPL (0.35) | LPLLIPG | |
| SCHEMBL31573229 | 0.76 | LPL (0.34) | LPLLIPG | |
| SCHEMBL15393294 | 0.76 | LPL (0.34) | LPLLIPG | |
| SCHEMBL28369018 | 0.74 | LPL (0.38) | LPLLIPGJAK2BTK | |
| SCHEMBL659113 | 0.74 | LPL (0.35) | LPLLIPG | |
| SCHEMBL19756678 | 0.74 | LPL (0.38) | LPLLIPGJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-11753421-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753421-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753421-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3705482-B1 | SILYLATION OF AROMATIC HETEROCYCLES BY EARTH ABUNDANT TRANSITION-METAL-FREE CATALYSTS | CALIFORNIA INST OF TECHN (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022135470-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-20220185828-A1 | Silylated Derivatives Of Aromatic Heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-06-16 | — | — | US | disclosed |
| US-20220185828-A1 | Silylated Derivatives Of Aromatic Heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-06-16 | — | — | US | disclosed |
| US-11312733-B2 | Silylated derivatives of aromatic heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210047348-A1 | Silylated Derivatives Of Aromatic Heterocycles | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2021-02-18 | — | — | US | disclosed |
| EP-2125794-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2125793-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-04-08 | — | — | US | disclosed |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-04-01 | — | — | US | disclosed |
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-03-25 | — | — | US | disclosed |
| EP-2155735-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-2155734-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008144223-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144222-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312733-B2 | Silylated derivatives of aromatic heterocycles | KCNH1, KCNH3, HNRNPH3 | LPL 4780/4885LIPG 4437/4885CYP2A6 2952/4885 |
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, BUB1B, BUB1 | LPL 4766/4885LIPG 4717/4885CYP2A6 4648/4885 |
| US-11753421-B2 | Silylated derivatives of aromatic heterocycles | KCNH1, KCNH3, HNRNPH3 | LPL 4780/4885LIPG 4437/4885CYP2A6 2952/4885 |
| US-20210047348-A1 | Silylated Derivatives Of Aromatic Heterocycles | KCNH1, KCNH3, HNRNPH3 | LPL 4780/4885LIPG 4437/4885CYP2A6 2952/4885 |
| US-20220185828-A1 | Silylated Derivatives Of Aromatic Heterocycles | KCNH1, KCNH3, HNRNPH3 | LPL 4780/4885LIPG 4437/4885CYP2A6 2952/4885 |
| US-20100081641-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, AURKC, BUB1B | LPL 4873/4885LIPG 4836/4885CYP2A6 4766/4885 |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | LPL 4576/4885LIPG 4649/4885CYP2A6 1744/4885 |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | LPL 4576/4885LIPG 4649/4885CYP2A6 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.